[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-366938-105":59,"doc-detail-366938-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","e2f-transcription-factors-as-multimodal-biomarkers-for-pan-cancer-management","E2F transcription factors as multimodal biomarkers for pan-cancer management","","E2F early transcription factors are analyzed for their roles across cancers and their value as multimodal biomarkers. E2F expression is systematically profiled using pan-cancer datasets (GEO, TCGA, cBioPortal, Kaplan–Meier Plotter, PrognoScan) to assess differential expression, prognostic associations, clinicopathologic stage links, mutation patterns, functional enrichment, and drug-sensitivity relationships. The study further connects E2F levels with microsatellite instability, tumor mutation burden, tumor microenvironment, immune checkpoint genes, and anti-PD-1/PD-L1 response, validates E2F5 by real-time PCR, and confirms that E2F5 promotes bladder cancer cell proliferation and migration.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/e2f-transcription-factors-as-multimodal-biomarkers-for-pan-cancer-management/366938/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/e2f-transcription-factors-as-multimodal-biomarkers-for-pan-cancer-management/366938.png","ImageObject",300,407,{"name":92,"@type":93},"anakgang17","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-27","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"What is the focus of the study on E2F genes?","Question",{"text":112,"@type":113},"The study characterizes E2F expression across multiple cancer types and evaluates whether E2F genes can predict prognosis and immunotherapy responses as multimodal biomarkers.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which datasets are used to assess E2F in pan-cancer?",{"text":117,"@type":113},"Public resources including GEO, TCGA, cBioPortal, Kaplan–Meier Plotter, and PrognoScan are used to compare E2F expression between normal and tumor tissues and to relate expression with clinical and molecular features.",{"name":119,"@type":110,"acceptedAnswer":120},"How is E2F5 validated and what functional effect is observed?",{"text":121,"@type":113},"E2F5 expression is validated using real-time PCR, and in vitro experiments show that E2F5 significantly promotes bladder cancer cell proliferation and migration.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},366938,1790391002,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31},962090883568,"https://ap-avatar.wpscdn.com/davatar_a8503ba1806abce46bf441b54a3ca4cd","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nE2F transcription factors as multimodal biomarkers for pancancer management  \nShaobo Yang1,2,4, Kai Li1,2,3,4, Yong Suo1,2,3,4, Zhe Zhang1,2, Houyuan Chen1,2, Yuda Lin1,2, Chong Fu1,2, Yunkai Qie1,2, Chong Shen1,2􀀍 & Hailong Hu1,2􀀍  \nEarly 2 factor (E2F) genes are transcription factors that interact with many DNAs and proteins. Studies have demonstrated that E2F genes can play an oncogenic role in different cancers, yet fewer have explored their effects on pan-cancers. In this study, E2F expression is systematically characterized in multiple types of cancer and its predictive value is determined. Several public databases (GEO, Cancer Genome Atlas (TCGA), cBioPortal, Kaplan–Meier Plotter and PrognoScan) were used to evaluate E2F genes differentially expressed between normal and tumor tissue in pan-cancer, we then investigated the correlation between expression levels of E2F and prognostic factors, clinicopathologic stage, gene mutation types, functional enrichment, drug sensitivity. This study also examined the relationship between microsatellite instability, tumor mutation burden, tumor microenvironment (TME), tumorrelated immune checkpoint genes, and immunotherapy response as well as the expression of E2F. Then, we examined potential signaling pathways by analyzing gene set enrichment analyses (GSEAs) . Finally, we performed the real-time PCR expression validation and in vitro functional experiments  \nof E2F5. The expression of E2F was upregulated in most tumor tissues compared to adjacent normal tissues. The expression of E2F family genes was highest in E2F4 and lowest in E2F7 in 33 TCGA cancers. E2F gene expression correlates significantly with prognosis in multiple cancer types, as well as RNArelated stemness score and DNA-related stemness score, immune and stromal scores. The E2F genes expression also related with immune subtype in pan-cancer. There existed a positive correlation between E2F2 expression level and Dasatinib sensitivity, negatively related to drug sensitivity of Nelarabine, XK-469, Cyclophosphamide, etc. Pazopanib, Doxorubicin, and Paclitaxel sensitivity was all positively associated with E2F5 expression. E2F genes high expression group showed significant positive or negative enrichment in multiple tumor-and immune-related pathways. In addition, we also discovered that the expression level of nearly all E2F genes was positively or negatively correlated with objective responses to anti-PD-1/PD-L1 across multiple immunotherapy cohort. The immune infiltration analysis of specific bladder cancer further showed the significant relationships between E2Fs copy number variations or mutation status, and infiltration level of different immune cells. Furthermore, differential expression validation and in vitro phenotypic experiments indicated that E2F5 significantly promoted BCa cells proliferation and migration. According to these analysis and validation results, E2F genes are relevant to the occurrence and progression of various cancers, which may be biomarkers for tumor diagnostics and prognosis. The discovery of new therapeutic targets can lead to reshaping TMEto promote tumor-suppressive metastasis rather than tumor-friendly metastasis.  \nKeywords Pan-cancer, E2F family, Prognosis, Immunotherapy response, Multi-omics  \nIn recent years, cancer has become one of the greatest threats to the health of the public. In fact, the treatment of various cancers has been greatly improved. At present, cancer is treated primarily with surgical procedures, chemotherapy, radiotherapy, and targeted therapies. The prognosis and survival rates of these therapies remain  \n1Department of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, No. 23, Pingjiang Road, Tianjin 300211, China. 2Tianjin Key Laboratory of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, Ch","cbCaii0tXHAXEvz1","https://ap.wps.com/l/cbCaii0tXHAXEvz1","pdf",10882093,"English","# Introduction\n## Objectives and data sources\n# Methods and analyses\n## Differential expression and prognostic evaluation\n## Functional enrichment, pathway analysis, and drug sensitivity\n## Links to MSI, TMB, TME, immune checkpoints, and immunotherapy response\n## Experimental validation and functional assays\n# Key findings\n## E2F expression patterns across tumors\n## Associations with survival and stemness scores\n## Immune-related correlations and biomarker potential\n# Conclusion","[{\"question\":\"What is the focus of the study on E2F genes?\",\"answer\":\"The study characterizes E2F expression across multiple cancer types and evaluates whether E2F genes can predict prognosis and immunotherapy responses as multimodal biomarkers.\"},{\"question\":\"Which datasets are used to assess E2F in pan-cancer?\",\"answer\":\"Public resources including GEO, TCGA, cBioPortal, Kaplan–Meier Plotter, and PrognoScan are used to compare E2F expression between normal and tumor tissues and to relate expression with clinical and molecular features.\"},{\"question\":\"How is E2F5 validated and what functional effect is observed?\",\"answer\":\"E2F5 expression is validated using real-time PCR, and in vitro experiments show that E2F5 significantly promotes bladder cancer cell proliferation and migration.\"}]","E2F transcription factors as multimodal biomarkers for pan-cancer management | PDF",1790168299]